Tag: SunPharma

Categories
Corporate

Sun Pharma buys Innovcare In ₹271-cr deal

India’s largest drugmaker, Sun Pharmaceutical Industries, has announced the acquisition of Mumbai-based Innovcare Lifesciences in an all-cash deal valued at ₹271.2 crore. The move is aimed at strengthening Sun Pharma’s presence in the fast-growing nutraceutical and cosmeceutical segments while expanding its overall healthcare portfolio.

Under the agreement, Sun Pharma will acquire 100% ownership of Innovcare Lifesciences, a company engaged in the marketing, distribution and sale of pharmaceutical, nutraceutical and cosmeceutical products. The transaction is expected to be completed on or before July 31, 2026.

The acquisition reflects Sun Pharma’s strategy of broadening its offerings beyond traditional prescription medicines. With increasing consumer focus on preventive healthcare, nutrition and wellness products, nutraceuticals have emerged as one of the fastest-growing segments in the healthcare industry. Innovcare’s portfolio is expected to help Sun Pharma deepen its presence in these categories.

Founded in 2014, Innovcare has built a business around health supplements, pharmaceutical products and personal care solutions. The company reported revenue of ₹94.06 crore in FY26, continuing a steady growth trend over the past three years. Its established distribution network and product portfolio were key factors behind the acquisition.

Sun Pharma described the purchase as a strategic investment designed to strengthen its product basket and enhance long-term growth opportunities. Industry analysts believe the deal will allow the pharmaceutical major to tap into rising demand for wellness and lifestyle-focused healthcare products, complementing its strong position in the prescription drug market.

The acquisition also highlights Sun Pharma’s continued focus on expansion through targeted investments. In recent years, the company has pursued several strategic initiatives to diversify its business and reinforce its leadership position in the healthcare sector.

Also Read: Aavas Financiers shares dips 3% after NHB flags concerns

Categories
Corporate

Sun Pharma to buy Organon for $11.75 bn

Sun Pharmaceutical Industries has announced plans to acquire US-based healthcare company Organon in a $11.75 billion deal, making it one of the biggest overseas acquisitions by an Indian company and the largest by an Indian pharma firm.

The acquisition is expected to significantly strengthen Sun Pharma’s global presence and diversify its product portfolio. Organon has a strong business in women’s health, biosimilars and established medicines, with operations across more than 140 countries.

Sun Pharma said the deal supports its long-term growth strategy and will help it expand in high-potential global healthcare segments. Industry experts believe Organon’s established brands and international reach can provide steady revenue growth for the Indian drugmaker.

The combined business is expected to have wider global reach, stronger product offerings and improved scale in key markets such as the US, Europe and emerging economies.

The transaction has been approved by the boards of both companies and is expected to close after regulatory and shareholder clearances.

Investors reacted positively to the announcement, with Sun Pharma shares gaining in early trade. Analysts said the acquisition reflects the growing confidence of Indian pharmaceutical companies in making large global bets.

Also Read: Trump hosts Crypto event as meme coin crashes

 

 

 

 

 

 

Categories
Corporate

Sun Pharma Q3 profit seen up 8% at ₹2,400 cr

Sun Pharmaceutical Industries Ltd is expected to report Q3 FY26 revenue of around ₹13,500 crore, up 8–10% year-on-year, while net profit is estimated at nearly ₹2,400 crore, reflecting an 8% annual increase, according to analyst estimates. EBITDA margins are likely to remain stable at 28–30%, supported by steady domestic growth and a favourable product mix.

Growth in the December quarter is expected to be led by Sun Pharma’s India formulations business, which continues to benefit from strong demand for chronic therapies and periodic price hikes. Analysts expect the domestic market to remain a key earnings driver, contributing consistently to both revenue growth and margin stability.

The company’s specialty drugs portfolio, including products such as Ilumya and Cequa, is expected to deliver stable sales during the quarter. However, higher spending on marketing and research and development is likely to limit margin expansion. While the specialty business remains strategically important for long-term growth, analysts believe profitability from this segment will take time to scale up.

In contrast, Sun Pharma’s US generics business is expected to remain largely flat, weighed down by persistent pricing pressure and intense competition. Limited new product launches and ongoing price erosion are likely to restrict growth in the US market, which has been a key headwind for Indian drugmakers in recent years.

Other international markets are expected to report modest performance, broadly in line with previous quarters. Cost controls and a stable operating environment are likely to help the company protect margins despite challenges in select geographies.

On the profitability front, earnings are expected to closely track operating performance, with no major one-off items anticipated during the quarter. Analysts will closely monitor management commentary on the outlook for the US generics business, progress in the specialty portfolio, and the pace of investment in research and development.

Also Read: Gold at ₹1.78 lakh, Silver above ₹4.10 lakh